BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY

Patent Number: WO-2023218051-A1

Publication Year: 2023

Application Year: 2023

Priority Year: 2022

Jurisdictions: WO

Status: N/A

Inventors:

BREIJ ESTHER BREIJ ESTHER C W BOROSS PETER BOROSS PETER IMLE ANDREA IMLE ANDREA NUERMBERGER KRISTINA NÜRMBERGER KRISTINA MUIK ALEXANDER MUIK ALEXANDER GIESEKE FRIEDERIKE GIESEKE FRIEDERIKE SAHIN UGUR SAHIN UGUR ALTINTAS ISIL ALTINTAS ISIL IOAN ANDREEA IOAN ANDREEA BEURSKENS FRANK BEURSKENS FRANK DE JONG ROB N DE JONG ROB N SCHUURMAN JANINE SCHUURMAN JANINE DE GOEJE PAULINE L DE GOEJE PAULINE LINDA SATIJN DAVID SATIJN DAVID P E

Applicants:

  1. Genmab (Denmark)
    2. [NORA names: Genmab; Private Research; Denmark; Europe, EU; Nordic; OECD]
  2. BioNTech (Germany)
    3. [NORA names: Germany; Europe, EU; OECD]

Abstract

The present invention provides combination therapy using a first binding agent comprising at least one binding region binding to CD27 in combination with a second binding agent comprising a first binding region binding to CD40 and a second binding region binding to CD137 to reduce progression or prevent progression of a tumor or treating cancer.

Patent Family Records (2)

BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY  

BioNTech (Germany), BioNTech SE, GENMAB AS, Genmab (Denmark) BREIJ ESTHER C W, BOROSS PETER, IMLE ANDREA, (...more)

2024, TW-202409090-A

BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY

BioNTech (Germany), BioNTech SE, GENMAB AS, Genmab (Denmark) BREIJ ESTHER, BOROSS PETER, IMLE ANDREA, (...more)

2023, WO-2023218051-A1

Data Provider: Digital Science

LINKS
+

External Systems

SUBJECTS
+

PATENT CATEGORIES
+

METRICS
+

Citation Metrics

Times Cited in Patents: 0external link

References to Patents: 51external link

References to Publications: 5external link